TY - CHAP M1 - Book, Section TI - Dose Adjustment in Renal and Hepatic Disease A1 - Hon, Yuen Yi A2 - Shargel, Leon A2 - Yu, Andrew B.C. PY - 2016 T2 - Applied Biopharmaceutics & Pharmacokinetics, 7e AB - List the common causes of chronic kidney disease (CKD) and describe how CKD affects drug elimination.Compare the advantages and disadvantages of the use of drugs or endogenous substances as markers for the measurement of renal function.Describe the relationships between creatinine clearance, serum creatinine concentration, and glomerular filtration rate.Explain and contrast the methods of Cockcroft–Gault and Modification of Diet in Renal Disease (MDRD) for the calculation of creatinine clearance.List the causes for fluctuating serum creatinine concentration in the body.Calculate the dose for a drug in a patient with renal disease.Describe quantitatively using equations how renal or hepatic disease can alter the disposition of a drug.Describe hemoperfusion and the limitations for its use.Distinguish between hemodialysis and peritoneal dialysis and calculate dose adjustments of a drug in patients undergoing dialysis.Describe the principle of the fraction of drug excreted unchanged (fe) method and how it is applied to adjust doses in renal disease.Explain the principle involved in the Giusti–Hayton method.Describe the effects of hepatic disease on the pharmacokinetics of a drug.List the reasons why dose adjustment in patients with hepatic impairment is more difficult than dose adjustment in patients with renal disease.Explain how liver function tests relate to drug absorption and disposition.List the pharmacokinetic properties of a drug for which dose adjustment would not be required in patients with renal or hepatic impairment. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1117902762 ER -